DTC
MRSN

Deep Track Capital’s Mersana Therapeutics MRSN Stock Holding History

Deep Track Capital’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,187
Closed -$2.6M – 70
2024
Q1 		$2.6M Buy
+23,187
New +$2.31M 0.07% 63

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deep Track Capital's MRSN Position: Q2 2024 in Review

Deep Track Capital sold out of Mersana Therapeutics (MRSN) in Q2 2024, closing a stake of 23,187 shares — an estimated $2.6M sold.

Deep Track Capital first reported a position in MRSN in Q1 2024 and held it in 1 quarter. The position peaked at $2.6M in Q1 2024. 120 funds tracked by Wall St. Rank hold MRSN as of Q2 2024.

  • Deep Track Capital reported no remaining Mersana Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Deep Track Capital sold 23,187 Mersana Therapeutics shares in Q2 2024, an estimated $2.6M.
  • Deep Track Capital first reported a position in Mersana Therapeutics in Q1 2024 and held it in 1 quarter.
  • Deep Track Capital's Mersana Therapeutics position peaked at $2.6M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2024.

Based on Deep Track Capital's 13F filing for Q2 2024, filed 14 Aug 2024.